Clinical trials
catalyst calendar across sponsors →Studies where MGTX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
5 interventional · 1 observational · 1 with posted results
Held by 10 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, D. E. Shaw & Co., Inc., CITADEL ADVISORS LLC, Point72 Asset Management, L.P., AQR CAPITAL MANAGEMENT LLC, +5 more) · FINRA short interest 8.3 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Long-term Follow-up of Gene Therapy for Radiation-Induced XerostomiaNCT06544798Number of participants with study drug-related adverse events and serious adverse eventsRandomized · Open-label · Treatment | Phase 2 | Enrolling by invitation | Genetic: AAV2-hAQP1 | Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands | 276 | Feb 2032 | ≤ 2,019 d | 2025-10-16 |
| Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson's DiseaseNCT05894343Number of participants with study drug-related adverse events and serious adverse eventsRandomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Genetic: AAV-GAD | Parkinson's Disease | 13 | Oct 2029 | ≤ 1,168 d | 2025-08-17 |
| A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late XerostomiaNCT05926765Change from Baseline to Month 12 in Xerostomia-specific Questionnaire (XQ) Total ScoreRandomized · Triple-masked · Treatment | Phase 2 | Active, not recruiting | Genetic: AAV2-hAQP1 Concentration 1, AAV2-hAQP1 Concentration 2, AAV2-hAQP1 Concentration 3, AAV2-hAQP1 Concentration 4 · Other: Placebo | Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands | 290 | Jun 2027 | ≤ 314 d | 2026-07-24 |
| Long-Term Follow-Up Study of AAV2hAQP1 for Radiation Induced XerostomiaNCT05060341observational• Incidence of AEs, treatment-emergent adverse events (TEAEs), and SAEs | — | Active, not recruiting | — | Radiation-induced Xerostomia | 22 | Mar 2027 | ≤ 223 d | 2026-07-22 |
| Safety of a Single Administration of AAV2hAQP1, an Adeno-Associated Viral Vector Encoding Human Aquaporin-1 to One Parotid Salivary Gland in People With Irradiation-Induced Parotid Salivary HypofunctionNCT02446249Safety of vectorOpen-label · Treatment | Phase 1 | Active, not recruiting | Biological: AAV2hAQP1 | Squamous Cell Head and Neck Cancer, Radiation Induced Xerostomia, Salivary Hypofunction | 17 | Jul 2026 | — | 2025-09-25 |
| A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's ParticipantsNCT05603312results2025-09-05Incidence of Adverse Events Related to the TreatmentRandomized · Triple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Genetic: AAV-GAD Low Dose, AAV-GAD High Dose · Procedure: Sham Surgery | Parkinson's Disease | 14 | 2024-09-06actual | — | 2025-09-05 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19